Over the last 7 days, the United States market has remained flat, yet it is up 22% over the past year with earnings expected to grow by 15% per annum in the coming years. In this context of steady ...

James initiated coverage on Regenxbio Inc . (NASDAQ:RGNX), bestowing an Outperform rating and setting a price target of $27.00 for the biotechnology company's shares. The firm's endorsement comes with ...